Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Boston Scientific Corp (BSX)

Boston Scientific Corp (BSX)
93.91 +0.24 (+0.26%) 11:57 ET [NYSE]
93.89 x 73 93.97 x 300
Realtime by (Cboe BZX)
93.89 x 73 93.97 x 300
Realtime 94.62 +0.95 (+1.01%) 09:28 ET
Quote Overview for Mon, Apr 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
93.72
Day High
95.28
Open 95.28
Previous Close 93.67 93.67
Volume 1,896,963 1,896,963
Avg Vol 9,635,616 9,635,616
Stochastic %K 41.89% 41.89%
Weighted Alpha +32.22 +32.22
5-Day Change +2.76 (+3.02%) +2.76 (+3.02%)
52-Week Range 66.80 - 107.17 66.80 - 107.17
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 138,544,480
  • Shares Outstanding, K 1,479,070
  • Annual Sales, $ 16,747 M
  • Annual Income, $ 1,854 M
  • EBIT $ 3,461 M
  • EBITDA $ 5,116 M
  • 60-Month Beta 0.73
  • Price/Sales 8.18
  • Price/Cash Flow 25.38
  • Price/Book 6.21

Options Overview Details

View History
  • Implied Volatility 39.81% ( -5.33%)
  • Historical Volatility 43.80%
  • IV Percentile 97%
  • IV Rank 66.12%
  • IV High 52.68% on 04/04/25
  • IV Low 14.68% on 08/13/24
  • Put/Call Vol Ratio 0.87
  • Today's Volume 2,453
  • Volume Avg (30-Day) 14,840
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 254,841
  • Open Int (30-Day) 216,831

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.67
  • Number of Estimates 10
  • High Estimate 0.68
  • Low Estimate 0.66
  • Prior Year 0.56
  • Growth Rate Est. (year over year) +19.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
85.98 +9.68%
on 04/07/25
Period Open: 97.16
104.35 -9.63%
on 03/25/25
-2.86 (-2.94%)
since 03/14/25
3-Month
85.98 +9.68%
on 04/07/25
Period Open: 95.65
107.17 -12.01%
on 02/05/25
-1.35 (-1.41%)
since 01/14/25
52-Week
66.80 +41.17%
on 04/22/24
Period Open: 68.07
107.17 -12.01%
on 02/05/25
+26.23 (+38.53%)
since 04/12/24

Most Recent Stories

More News
What to Expect From Boston Scientific’s Q1 2025 Earnings Report

Boston Scientific is expected to release its fiscal first-quarter earnings later this month, and analysts project a double-digit profit rise.

XLV : 137.46 (+0.43%)
BSX : 93.88 (+0.22%)
$SPX : 5,397.27 (+0.63%)
3 Market-Beating Stocks with Competitive Advantages

3 Market-Beating Stocks with Competitive Advantages

BSX : 93.88 (+0.22%)
BBSI : 39.81 (-0.08%)
IOT : 37.06 (-1.93%)
Q4 Rundown: Abbott Laboratories (NYSE:ABT) Vs Other Medical Devices & Supplies - Diversified Stocks

Q4 Rundown: Abbott Laboratories (NYSE:ABT) Vs Other Medical Devices & Supplies - Diversified Stocks

COO : 78.01 (+0.71%)
ABT : 127.53 (+0.51%)
SYK : 350.80 (+0.15%)
BSX : 93.88 (+0.22%)
NEOG : 5.55 (-0.54%)
GEHC Stock Gains Following Buyout Completion to Boost Its PDx Arm

GE HealthCare Technologies Inc. GEHC, yesterday, announced the completion of its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (“NMP”) from Sumitomo Chemical, giving it full...

BSX : 93.88 (+0.22%)
COR : 282.79 (-0.54%)
GEHC : 63.33 (+0.83%)
CAH : 132.78 (+0.77%)
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024

Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024

BSX : 93.88 (+0.22%)
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval

DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM). The...

BSX : 93.88 (+0.22%)
COR : 282.79 (-0.54%)
CAH : 132.78 (+0.77%)
DXCM : 67.08 (+1.42%)
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With an...

BSX : 93.88 (+0.22%)
COR : 282.79 (-0.54%)
CAH : 132.78 (+0.77%)
DXCM : 67.08 (+1.42%)
BDX Stock Declines Following Class I Classification for Alaris Recall

Becton, Dickinson and Company’s BDX, or popularly known as BD, initiated the recall of its infusion pumps last month after customer reports indicated software issues, potentially leading to inaccurate...

BSX : 93.88 (+0.22%)
BDX : 203.78 (+0.99%)
COR : 282.79 (-0.54%)
CAH : 132.78 (+0.77%)
Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?

The broader market rally, which pushed the benchmark to a two-week record high yesterday, fueled by tech giants like NVIDIA and Tesla, has provided a much-needed breather for investors. This has potentially...

NVDA : 109.73 (-1.08%)
ABT : 127.53 (+0.51%)
TSLA : 248.94 (-1.34%)
BSX : 93.88 (+0.22%)
MDT : 83.55 (+0.78%)
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic

For Immediate ReleasesChicago, IL – March 25, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

ABT : 127.53 (+0.51%)
BSX : 93.88 (+0.22%)
MDT : 83.55 (+0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and...

See More

Key Turning Points

3rd Resistance Point 97.39
2nd Resistance Point 95.94
1st Resistance Point 94.80
Last Price 93.88
1st Support Level 92.21
2nd Support Level 90.76
3rd Support Level 89.62

See More

52-Week High 107.17
Last Price 93.88
Fibonacci 61.8% 91.75
Fibonacci 50% 86.99
Fibonacci 38.2% 82.22
52-Week Low 66.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar